Yeon H. Park

A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial

Gabriel N. Hortobágyi, Joohyuk Sohn, F. Melo Cruz et al. · Annals of Oncology · 2024 · 90 citations · Full text

Medicine, Oncology, Pharmacology +17

Abstract GS3-04: GS3-04 Capivasertib and fulvestrant for patients with aromatase inhibitor-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: results from the Phase III CAPItello-291 trial

Nicholas C. Turner, Mafalda Oliveira, Sacha J. Howell et al. · Cancer Research · 2023 · 30 citations

Medicine, Oncology, Pharmacology +17

Abstract PD11-08: PD11-08 Trastuzumab deruxtecan (T-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic hormone receptor-negative (HR−), HER2-low breast cancer: updated results from BEGONIA, a phase 1b/2 study

Peter Schmid, Piotr J. Wysocki, Yeon H. Park et al. · Cancer Research · 2023 · 30 citations

Medicine, Oncology, Pharmacology +17

Induction of intestinal ischemia reperfusion injury by portal vein outflow occlusion in rats

Marco Vincenti, Matthias Behrends, Yeon H. Park et al. · Journal of Gastroenterology · 2010 · 24 citations

Medicine, Physiology, Surgery +13

Abstract GS2-01: GS2-01 Trastuzumab deruxtecan vs physician’s choice in patients with HER2+ unresectable and/or metastatic breast cancer previously treated with trastuzumab emtansine: primary results of the randomized, phase 3 study DESTINY-Breast02

Ian E. Krop, Yeon H. Park, Sung‐Bae Kim et al. · Cancer Research · 2023 · 23 citations

Medicine, Oncology, Pharmacology +16